News

Divarasib plus pembrolizumab shows strong responses in patients with advanced KRAS G12C+ non-small cell lung cancer, according to the results of the Krascendo 170 study, presented today at ASCO 2026.

Dana-Farber’s Katherine Janeway, M.D., discusses how reimbursement policies for molecular diagnostics have failed to keep pace with scientific evidence, leaving gaps in the care for pediatric bone cancer patients.

A collagen implant that releases radiation after brain tumor surgery reduced cancer recurrence and increased overall survival, according to results presented at ASCO’s annual meeting.

Dana-Farber’s Katherine Janeway, M.D., discusses how molecular biomarkers inform treatment decisions in children and adolescents with the bone cancers Ewing sarcoma and osteosarcoma.

Seven-year CROWN trial data show lorlatinib's median PFS still not reached in advanced ALK-positive NSCLC, with a 94% reduction in intracranial progression risk.

Afrezza is an inhaled insulin and the first needle-free insulin option for children with diabetes.

Because pharmacy benefit managers and third-party administrators earn more from arrangements with smaller safety-net providers, there are incentives to shift attribution of prescriptions toward those providers.

Eli Lilly and Company is acquiring three vaccine companies to expand its reach into infectious disease research and prevention.

Hepcludex is an antiviral to treat adults living with chronic hepatitis D virus infection, a serious liver disease that occurs as a co-infection in people with chronic hepatitis B virus.

Nubeqa (darolutamide) may have fewer negative cognitive side effects because it doesn't cross the blood-brain barrier.

Women with high-grade serous ovarian cancer who fasted around chemotherapy sessions had lower insulin levels, improved chemotherapy responses and potentially longer progression-free survival compared with patients who ate normally, according to findings from an Italian study presented at the 2026 American Society of Clinical Oncology Annual Meeting.

GLP-1 receptor agonist drugs may reduce cancer progression in lung, breast, colorectal, and liver cancers by 38% to 50%, and high GLP-1 receptor expression correlates with 33% lower mortality risk.

By targeting a specific pathway, the mineralocorticoid receptor, Kerendia is able to stop the cascade of inflammation and fibrosis that leads to kidney disease.

Insurance status was strongly associated with lung screening, with those having military-related coverage more likely to get screene than others.

A CDC study found people vaccinated within the past six months were nearly half as likely to transmit SARS-CoV-2 to those they live with.

In this conversation, Jerome Siegel, Ph.D., professor of psychiatry, David Geffen School of Medicine at UCLA and director of the Center for Sleep Research at the Semel Institute for Neuroscience and Human Behavior at UCLA, explains the findings of his latest study about the neuron damage associated with narcolepsy.

Milliman’s Medical Index finds delivery system consolidation, specialty drug growth, and site-of-care shifts are contributing to employee healthcare costs.

Affordable Care Act Marketplace deductibles hit a record 37% increase in 2026 as expired enhanced tax credits pushed millions of enrollees toward cheaper, higher-deductible bronze plans.

Findings may help with the selection problem of which ALK inhibitor to use, as the number of treatments in that category for non-small cell lung cancer has increased.

Researchers found that the cost of recommended sunscreen use can range from approximately $40 to more than $1,400 per year, depending on sunscreen prices and clothing choices.

GLP-1 medications, especially for diabetes, will remain an influential cost driver in drug spending this year, supported by broader prescriber adoption and patient demand.

Immgolis and Immgolis Intri have the same indications as Simponi and Simponi Aria, treating patients with rheumatoid arthritis and ulcerative colitis. The biosimilars will be available in the fourth quarter of this year.

Navitus clients saw prescription drug costs rise 8.4% in 2025, driven by specialty medications, GLP-1s, oncology and dermatology spending.

Self-insured employers and other payers are the startup's customers, but Aradigm CEO and co-founder Will Shrank says the company is looking to bridge the gaps among all stakeholders in burgeoning cell and gene therapy category.

Shrank, a longtime member of the MHE editorial advisory board, discusses the mainstreaming of CAR-T therapy and still-unique aspects of gene therapy

The FDA approved two new cancer drugs this week, one for rare non-Hodgkin lymphoma and another for elderly acute myeloid leukemia patients.